Neuroblastoma Market Report 2026

Neuroblastoma Market Overview

• Neuroblastoma market size has reached to $3.14 billion in 2025 • Expected to grow to $4.12 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rising Childhood Cancer Incidence Driving Growth In The Market • Market Trend: Advancements In Targeted Therapies For High-Risk Neuroblastoma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuroblastoma Market?

Neuroblastoma is a type of cancer that primarily affects children and arises from immature nerve cells called neuroblasts. It commonly develops in the adrenal glands, located on top of the kidneys, and occurs in other areas of the abdomen, chest, neck, or pelvis. The cancer can cause symptoms such as abdominal pain, swelling, fatigue, and sometimes bone pain or lumps. The main product types of neuroblastoma are tablets, vaccines, and others. Tablets are solid, oral doses containing active ingredients, binders, and fillers, used in neuroblastoma treatment for administering chemotherapy or targeted therapy drugs. This consists of various treatment types, such as chemotherapy, immunotherapy, and others, and is distributed by several distribution channels, including online and offline. It is used by various end users, such as hospitals and clinics.

What Is The Neuroblastoma Market Growth Forecast?

The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to expansion of targeted therapy research, increasing investment in cell therapy products, rising adoption of precision oncology methods, development of new pediatric immunotherapy solutions, growth in advanced diagnostic imaging for early detection. Major trends in the forecast period include increasing adoption of immunotherapy vaccines for pediatric cancer, growing use of targeted oral chemotherapy tablets, rising development of monoclonal antibody treatments, expansion of cell therapy and regenerative oncology approaches, increasing focus on early diagnosis and symptom management.

Global Neuroblastoma Market Segmentation

1) By Product Type: Tablets, Vaccines, Other Product Types 2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types 3) By Distribution Channel: Online, Offline 4) By End-User: Hospitals, Clinics Subsegments: 1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets 2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines 3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products

What Is The Driver Of The Neuroblastoma Market?

The increase in the incidence of childhood cancer is expected to propel the growth of the neuroblastoma market going forward. Childhood cancer is a collection of cancers that primarily affect children and adolescents, commonly targeting organs such as the brain, blood, and bones and necessitating specialized treatment approaches. The rise in the incidence of childhood cancer is attributed to factors such as improved diagnostic techniques, better awareness, environmental exposures, genetic predispositions, and advances in medical research. Neuroblastoma treatment provides targeted therapies for childhood cancer, enabling early and effective intervention that lowers the risk of recurrence and improves outcomes for young patients. For instance, in May 2024, according to the American Cancer Society, a US-based professional organization company, in 2024, approximately 9,620 children under the age of 15 in the United States are projected to be diagnosed with cancer, an increase from 5,290 cases in 2023. Therefore, the increase in the incidence of childhood cancer is driving the growth of the neuroblastoma industry.

Key Players In The Global Neuroblastoma Market

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

Global Neuroblastoma Market Trends and Insights

Major companies operating in the neuroblastoma market are focusing on developing advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to target and treat cancer cells more effectively and safely specifically. A humanized anti-GD2 monoclonal antibody is engineered to target the GD2 molecule on cancer cells with reduced immune rejection by incorporating human components. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is designed to treat newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. Under the terms of the agreement, Renaissance has secured exclusive rights to develop, manufacture, and commercialize Hu14.18 across key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

What Are Latest Mergers And Acquisitions In The Neuroblastoma Market?

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. This acquisition grants Ligand royalty rights to Qarziba and aims to expand its commercial royalty portfolio with high-value immunotherapy for high-risk neuroblastoma, supporting growth by generating long-term, predictable revenue from a diversified set of key products. Apeiron Biologics AG is an Austria-based biotech company that develops immunotherapies for neuroblastoma.

Regional Outlook

North America was the largest region in the neuroblastoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuroblastoma Market?

The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuroblastoma Market Report 2026?

The neuroblastoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuroblastoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.